The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Markers of inflammation have been associated with outcomes in various cancers. The purpose of this study was to evaluate whether systemic inf lammatory markers and their f luctuations can predict survival and chemotherapy response in patients with metastatic gastric cancer (mGC). Methods: We retrospectively reviewed the records of 502 patients who received first-line palliative chemotherapy for mGC between 2007 and 2013. The neutrophil- to-lymphocyte ratio (NLR) and modified Glasgow prognostic score (mGPS) were assessed before and after chemotherapy to evaluate their association with survival. The NLR values were categorized into two groups based on a cut-off value of 3; mGPS values were classified as high versus low. Results: High prechemotherapy NLR was significantly associated with poor overall survival on univariate analysis (p = 0.002). On multivariate analysis, high prechemotherapy NLR (hazard ratio, 1.43; p < 0.001) was an independent prognostic factor for poor overall survival. However, the prechemotherapy mGPS was not significantly associated with survival. Continuously high NLR or a shift to high NLR postchemotherapy was associated with poor chemotherapy response as well as survival, while NLR reduction was associated with a good response (linear by linear association, p < 0.001) and a favorable prognosis. Conclusions: Prechemotherapy NLR can be used as a prognostic factor in mGC, while the postchemotherapy NLR value may predict the chemotherapeutic response and prognosis. In contrast, mGPS has limited prognostic utility in mGC.
Abstract
Background/Aims: Markers of inflammation have been associated with outcomes in various cancers. The purpose of this study was to evaluate whether systemic inf lammatory markers and their f luctuations can predict survival and chemotherapy response in patients with metastatic gastric cancer (mGC). Methods: We retrospectively reviewed the records of 502 patients who received first-line palliative chemotherapy for mGC between 2007 and 2013. The neutrophil- to-lymphocyte ratio (NLR) and modified Glasgow prognostic score (mGPS) were assessed before and after chemotherapy to evaluate their association with survival. The NLR values were categorized into two groups based on a cut-off value of 3; mGPS values were classified as high versus low. Results: High prechemotherapy NLR was significantly associated with poor overall survival on univariate analysis (p = 0.002). On multivariate analysis, high prechemotherapy NLR (hazard ratio, 1.43; p < 0.001) was an independent prognostic factor for poor overall survival. However, the prechemotherapy mGPS was not significantly associated with survival. Continuously high NLR or a shift to high NLR postchemotherapy was associated with poor chemotherapy response as well as survival, while NLR reduction was associated with a good response (linear by linear association, p < 0.001) and a favorable prognosis. Conclusions: Prechemotherapy NLR can be used as a prognostic factor in mGC, while the postchemotherapy NLR value may predict the chemotherapeutic response and prognosis. In contrast, mGPS has limited prognostic utility in mGC.
참고문헌 (35)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)[DOI]
- Digklia A, "Advanced gastric cancer: current treatment landscape and future perspectives", World J Gastroenterol, 22, pp.2403~2414 (2016)[DOI]
- Maconi G, "Role of symptoms in diagnosis and outcome of gastric cancer", World J Gastroenterol, 14, pp.1149~1155 (2008)[DOI]
- Yang D, "Survival of metastatic gastric cancer: significance of age, sex and race", ethnicity, 2011, pp.2, 77~84
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial", Lancet, 376, pp.687~697 (2010)[DOI]
- Wagner AD, "Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data", J Clin Oncol, 24, pp.2903~2909 (2006)[DOI]
- Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)[DOI]
- Yamada Y, "Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer", Ann Oncol, 26, pp.141~148 (2015)[DOI]
- Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)[DOI]
- Mohri Y, "Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: a single institutional cohort study", Medicine (Baltimore), 95, pp.e3125~ (2016)[DOI]
- Li QQ, "Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy", Asian Pac J Cancer Prev, 15, pp.945~950 (2014)[DOI]
- Cho IR, "Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer", Gastric Cancer, 17, pp.703~710 (2014)[DOI]
- Jiang X, "Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer", Br J Cancer, 107, pp.275~279 (2012)[DOI]
- Hsieh MC, "A prognostic model using inflammation- and nutrition-based scores in patients with metastatic gastric adenocarcinoma treated with chemotherapy", Medicine (Baltimore), 95, pp.e3504~ (2016)[DOI]
- Hsu JT, "Prognostic value of the preoperative neutrophil to lymphocyte ratio in resectable gastric cancer", Medicine (Baltimore), 94, pp.e1589~ (2015)[DOI]
- Yu L, "Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer", World J Gastroenterol, 21, pp.6280~6286 (2015)[DOI]
- Seung Jun Lee, "Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study", The Korean Journal of Internal Medicine, 31(5), pp.891~898 (2016), 대한내과학회[DOI]
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)[DOI]
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)[DOI]
- Balkwill F, "Inflammation and cancer: back to Virchow?", Lancet, 357, pp.539~545 (2001)[DOI]
- Kishiki T, "Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer", Am J Surg, 206, pp.234~240 (2013)[DOI]
- Schwartz LH, "Evaluation of lymph nodes with RECIST 1.1", Eur J Cancer, 45, pp.261~267 (2009)[DOI]
- Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)[DOI]
- Fang H, "Targeting the tumor microenvironment: from understanding pathways to effective clinical trials", Cancer Res, 73, pp.4965~4977 (2013)[DOI]
- Dumitru CA, "Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression", Semin Cancer Biol, 23, pp.141~148 (2013)[DOI]
- Smyth MJ, "Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity", Adv Immunol, 90, pp.1~50 (2006)
- Seock-Ah Im, "The Prognostic Significance of the Overexpression of HER-2", neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2, Cancer Research and Treatment, pp.2003, 35(2)[DOI]
- Song Y, "Relationship between HER2", neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma, 2010, pp.29, 76~81
- Forrest LM, "Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer", Br J Cancer, 89, pp.1028~1030 (2003)[DOI]
- Wook Jin Choi, "Nutritional Care of Gastric Cancer Patients with Clinical Outcomes and Complications: A Review", Clinical Nutrition Research, 5(2), pp.65~78 (2016), 한국임상영양학회
- Tan CS, "The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study", Support Care Cancer, 23, pp.385~391 (2015)[DOI]
- Dutta S, "A comparison of POSSUM and GPS models in the prediction of post-operative outcome in patients undergoing oesophago-gastric cancer resection", Ann Surg Oncol, 18, pp.2808~2817 (2011)[DOI]
- Walsh SM, "Does the modified Glasgow prognostic score (mGPS) have a prognostic role in esophageal cancer?", J Surg Oncol, 113, pp.732~737 (2016)[DOI]
- Ostrand-Rosenberg S, "Myeloid-derived suppressor cells: linking inflammation and cancer", J Immunol, 182, pp.4499~4506 (2009)[DOI]
- Ohki S, "Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer", Oncol Rep, 28, pp.453~458 (2012)[DOI]